Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMarch 4, 2020/0 Comments/in Publications /by David Anderson /wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2020-03-04 11:23:102020-03-04 11:23:10Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Leave a Reply
Want to join the discussion?Feel free to contribute!